<DOC>
	<DOCNO>NCT00303732</DOCNO>
	<brief_summary>RATIONALE : Vatalanib everolimus may stop growth tumor cell block blood flow tumor block enzyme need cell growth . PURPOSE : This phase I trial study side effect best dose vatalanib everolimus see well work treat patient advance solid tumor .</brief_summary>
	<brief_title>Vatalanib Everolimus Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose ( MTD ) vatalanib everolimus patient advance solid tumor . - Determine safety tolerability vatalanib everolimus patient advance solid tumor . - Evaluate safety tolerability vatalanib everolimus MTD patient metastatic renal cell carcinoma ( RCC ) . Secondary - Describe non dose-limiting toxic effect associate vatalanib everolimus . - Describe pharmacokinetics vatalanib everolimus patient advance solid tumor . - Determine functional extent mTOR inhibition change phosphorylation status S6K protein peripheral blood mononuclear cell patient treat vatalanib everolimus . - Describe clinical response see patient metastatic RCC dose-expansion cohort treat MTD . - Observe overall survival RCC patient treat vatalanib everolimus . - Determine time progression patient RCC treat vatalanib everolimus . OUTLINE : This phase I dose-escalation study follow phase Ib study . - Phase I ( solid tumor ) : Patients receive oral vatalanib day 1-28 oral everolimus day 15-28 course 1 day 1-28 subsequent course . Treatment repeat every 28 day 12 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos vatalanib everolimus maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . - Phase Ib ( renal cell carcinoma ) : Patients receive oral vatalanib oral everolimus MTD day 1-28 . Treatment repeat every 28 day 12 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 6 month . PROJECTED ACCRUAL : A total 44 patient accrue study .</detailed_description>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Vatalanib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm solid tumor radiographic evidence metastatic disease No standard therapy exist ( phase I ) Unresectable metastatic renal cell carcinoma ( phase Ib ) PATIENT CHARACTERISTICS : Karnofsky performance status 70100 % Absolute neutrophil count ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Hemoglobin ≥ 9 g/dL AST ALT ≤ 2.5 time upper limit normal ( ULN ) Total cholesterol &lt; 300 mg/dL Triglycerides &lt; 350 mg/dL Bilirubin ≤ 1.5 time ULN Creatinine ≤ 1.5 time ULN OR creatinine clearance &gt; 40 mL/min Negative proteinuria dip stick OR total urinary protein ≤ 500 mg No uncontrolled high blood pressure , history labile hypertension , history poor compliance antihypertensive regimen No unstable angina pectoris No symptomatic congestive heart failure ( New York Heart Association class III IV heart disease ) No uncontrolled serious cardiac arrhythmia ( symptomatic supraventricular tachycardia ventricular tachycardia/fibrillation ) No myocardial infarction past 6 month No uncontrolled diabetes No interstitial pneumonia extensive symptomatic interstitial fibrosis lung No active uncontrolled infection No uncontrolled hyperlipidemia No chronic renal disease No acute chronic liver disease ( e.g. , hepatitis cirrhosis ) No impaired gastrointestinal ( GI ) function OR GI disease may significantly alter absorption vatalanib everolimus , include follow : Ulcerative disease Uncontrolled nausea vomit solid food Watery diarrhea &gt; 5 time daily Malabsorption syndrome Bowel obstruction Inability swallow tablets No confirm HIV infection Not pregnant Negative pregnancy test Fertile patient must use effective contraception No concurrent severe and/or uncontrolled medical condition would preclude study participation PRIOR CONCURRENT THERAPY : Recovered prior therapy No prior antivascular endothelial growth factor therapy More 4 week since prior major surgery* ( laparotomy ) More 2 week since prior minor surgery* More 4 week since prior chemotherapy ( 6 week mitomycin C nitrosoureas ) More 6 week since prior antibody therapy More 2 week since prior biologic/immunotherapy More 2 week since prior limitedfield radiotherapy More 4 week since prior fullfield radiotherapy More 4 week since prior investigational agent Prior transfusion allow provide blood count stable &gt; 2 week Concurrent epoetin alfa allow No concurrent warfarin similar oral anticoagulant metabolize cytochrome P450 system Heparin low molecular weight heparin allow NOTE : *Insertion vascular access device consider major minor surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>recurrent renal cell cancer</keyword>
	<keyword>stage IV renal cell cancer</keyword>
</DOC>